Shop Now Contact

Anti-Human PCSK9 (Evolocumab Biosimilar)

Cat # Size Price Quantity
5028011 mg$190
5028025 mg$750
50280320 mg$1800

  Bulk/Custom

Product Details

CloneEvolocumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human PCSK9 (Evolocumab Biosimilar)
IsotypeHuman IgG2
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman PCSK9
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
RRIDAB_3739304
Target NamePCSK9, Neural Apoptosis Regulated Convertase 1 (NARC1)
Antibody TypeRecombinant
Research AreasMetabolism, Cholesterol
See All FormatsClone Evolocumab

Background Information

Evolocumab is a fully human monoclonal antibody belonging to the immunoglobulin G2 (IgG2) subclass, engineered to bind with high specificity and affinity to proprotein convertase subtilisin/kexin type 9 (PCSK9). Structurally, it is a glycoprotein with a molecular weight of approximately 144 kilodaltons (kDa). Evolocumab is composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming the canonical Y-shaped structure typical of antibodies. It is expressed in mammalian cell systems, such as Chinese Hamster Ovary (CHO) cells, which facilitate proper folding, disulfide linkages, and glycosylation for stability and bioactivity.

The variable domains of Evolocumab’s heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that create an antigen-binding site capable of specifically recognizing PCSK9. This serine protease circulates in plasma and plays a central role in lipid metabolism by regulating the degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes. Evolocumab binds PCSK9 with sub-nanomolar affinity through non-covalent interactions such as hydrogen bonding, electrostatic attraction, and hydrophobic contacts. By occupying its active binding interface, Evolocumab prevents PCSK9 from associating with LDLR, thereby inhibiting receptor internalization and degradation. This molecular blockade preserves LDLR availability on cell surfaces, enhancing receptor recycling and sustaining receptor-mediated endocytosis processes in biochemical systems.

The Fc (fragment crystallizable) portion of Evolocumab, derived from human IgG2, contributes to its structural integrity and extended serum half-life via interaction with the neonatal Fc receptor (FcRn), which recycles the antibody and protects it from lysosomal degradation. The IgG2 backbone is selected to minimize effector functions, reducing complement activation and antibody-dependent cellular cytotoxicity (ADCC).

Data Sheets

Anti-Human PCSK9 (Evolocumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.